

ANUH PHARMA LTD.							
CIN No.L24230MH1960PLC011586							
Regd. Office : ,3-A, North Wing, Shiv Sagar Estate, Dr. Annie Basent Road, Worli, Mumbai-400018							
UNAUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 30th SEPTEMBER-2014							
Unaudited						Rs. In Lacs	
Sr. No.	Particulars	Quarter Ended			Year to Date ended		Audited Previous year ended 31/03/2014
		Sep 2014	Jun 2014	Sep 2013	Sep 2014	Sep 2013	
PART-I							
1	Net Sales / Income From Operation	7,112.70	7,533.70	6,741.92	14,646.39	12,297.94	26,639.77
2	Expenditure						
a	(Increase)/Decrease In Stock	(460.85)	(407.08)	689.56	(667.93)	221.64	351.47
b	Cost of Materials Consumed	5,935.39	6,291.81	4,773.87	12,227.20	9,640.63	20,993.06
c	Purchase of Stock -In-Trade	-	-	-	-	-	82.89
d	Employees Benefit Expense	131.79	141.57	111.28	273.36	220.70	466.58
e	Processing Charges	232.05	178.63	90.13	410.67	191.10	550.53
f	Power Fuel & Other Utility	85.74	84.45	75.00	170.19	135.07	281.72
g	Depreciation	45.00	45.00	51.00	90.00	90.00	174.61
h	Other Expenses	371.98	383.88	201.11	755.86	511.66	1,236.93
	Total :-	6,341.11	6,718.25	5,992.75	13,059.36	11,010.80	24,137.78
3	Profit From Operation before Finance Cost & Exceptional Item (1-2)	771.59	815.44	749.18	1,587.04	1,287.15	2,501.98
4	a Other Income	71.28	140.94	93.31	212.22	238.66	414.87
	b Exchange Gain/(Loss)	(129.05)	(19.47)	(233.28)	(148.52)	(464.90)	(358.81)
5	Profit before Interest & Exceptional Items(3+4)	713.82	936.91	609.23	1,650.73	1,060.91	2,556.04
6	Finance Cost	0.34	0.68	1.59	1.02	1.94	10.39
7	Profit after Interest but before Exceptional Item(5-6)	713.48	936.23	607.64	1,649.71	1,058.97	2,547.65
8	Exceptional Item	-	-	-	-	-	-
9	Profit(+) / Loss(-) before Tax (7+8)	713.48	936.23	607.64	1,649.71	1,058.97	2,547.65
10	Tax Expenses	238.00	280.00	193.48	518.00	300.00	788.65
11	Net Profit(+) / Loss(-) from Ordinary Activities after Tax (9-10)	475.48	656.23	414.16	1,131.71	758.97	1,759.00
12	Extraordinary Item (Net of Tax Expenses)	-	-	-	-	-	-
13	Net Profit(+) / Loss(-) for the period (11-12)	475.48	656.23	414.16	1,131.71	758.97	1,759.00
14	Paid up Equity Share Capital	417.60	417.60	417.60	417.60	417.60	417.60
15	Reserves excluding Revolution Reserves as per Balance sheet of Previous Accounting Year						6,170.53
16	Earning per Share(EPS) Face Value of Rs.5/-						
a	Basic & Diluted EPS before Extraordinary Items for the period, for the year to date and for the previous year(not to be annualised)	5.69	7.86	4.96	13.55	9.09	21.06
b	Basic & Diluted EPS after Extraordinary Items for the period, for the year to date and for the previous year(not to be annualised)	5.69	7.86	4.96	13.55	9.09	21.06
PART II							
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	Number of Shares	2,924,342	2,918,162	2,923,062	2,924,342	2,923,062	2,918,062
	Percentage of Shareholding	35.01	34.94	35.00	35.01	35.00	34.94
2	Promoters & Promoter group Shareholding						
a	Pledged/Encumbered						
	-Number of Shares	NII	NII	NII	NII	NII	NII
	-Percentage of Shares(as a % of the total share holding of promoters and promoter group)						
	-Percentage of shares(as a % of the total share capital of the company)						
b	Non Encumbered						
	-Number of Shares	5,427,658	5,433,938	5,428,938	5,427,658	5,428,938	5,433,938
	-Percentage of Shares(as a % of the total share holding of promoters and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	-Percentage of shares(as a % of the total share capital of the company)	64.99	65.06	65.01	64.99	65.01	65.06
Sr. No.	Particulars	3 months ended					
		30th September '14					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter		NII				
	Received during the quarter		NII				
	Disposed of during the quarter		NII				
	Remaining unresolved at the end of the quarter		NII				
NOTE :							
1	The above results were reviewed by Audit Committee and taken on record by the Board of Director of the Company at their meeting held on 14th November- 2014.						
2	The Company's operation fall under single segment namely "Bulk Drugs & Chemicals".						
3	Pursuant to the enactment of Companies Act 2013 effective 1st April, 2014, the managment of the company has identified tangible fixed assets and is in the process of evaluating useful life of of the same, the impact of which, if any, on depreciation would be accounted for in the subsequent quarters.						
Place :	Mumbai						
Date :	14th November-2014						
For ANUH PHARMA LTD.							

For ANUH PHARMA LTD.

Bipin N. Shah

**BIPIN N. SHAH
MANAGING DIRECTOR**

ANUH PHARMA LIMITED
STATEMENT OF ASSETS & LIABILITIES

₹. In Lacs

Particulars		As at September 30, 2014 Unaudited	As at March 31, 2014 Audited
		₹	₹
I. EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share capital		418	418
(b) Reserves and surplus		9,107	8,171
(c) Money received against share warrants		-	-
		9,525	8,588
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long-term borrowings		-	-
(b) Deferred tax liabilities (net)		24	24
(c) Other long term liabilities		-	-
(d) Long-term provisions		21	26
		45	50
4 Current liabilities			
(a) Short-term borrowings		531	-
(b) Trade payables		6,052	6,002
(c) Other current liabilities		714	177
(d) Short-term provisions		1,327	1,509
		8,624	7,688
TOTAL		18,195	16,326
II. ASSETS			
Non-current assets			
1 (a) Fixed assets			
(i) Tangible assets		1,147	1,205
(ii) Intangible assets		9	10
(iii) Capital work-in-progress		18	18
(iv) Intangible assets under development		-	-
		1,174	1,233
(b) Non-current investments		453	803
(c) Deferred tax assets (net)		-	-
(d) Long-term loans and advances		77	133
(e) Other non-current assets		-	-
		530	936
2 Current assets			
(a) Current investments		1,736	1,880
(b) Inventories		3,795	1,932
(c) Trade receivables		7,516	7,475
(d) Cash and bank balances		1,548	1,547
(e) Short-term loans and advances		1,869	1,299
(f) Other current assets		28	24
		16,492	14,157
TOTAL		18,195	16,326

Place : Mumbai

Date : 14th November-2014

For ANUH PHARMA LTD.

Bipin N. Shah

BIPIN N. SHAH
MANAGING DIRECTOR

S. I. MOGUL & CO.

CHARTERED ACCOUNTANTS



73-B MITTAL COURT · NARIMAN POINT · MUMBAI 400021 · INDIA

TEL : (91 22) 22842159, 22842093 · FAX : (91 22) 22822743 · E-MAIL : SIMCO@SIMOGUL.COM · WEBSITE : SIMOGUL.COM

LIMITED REVIEW REPORT

TO THE BOARD OF DIRECTORS OF ANUH PHARMA LIMITED

We have reviewed the accompanying statement of unaudited financial results of **Anuh Pharma Limited ("Company")** for the period ended on September 30, 2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement ("SRE") 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mumbai, India: November 13, 2014

For S. I. MOGUL & CO.
Chartered Accountants
Firm Registration No. 106512W


S. I. Mogul
Partner

Membership No. 5572